Sun Pharmaceutical Industries Ltd has officially introduced its global innovative biologic Ilumya® (Tildrakizumab) in India for the treatment of moderate-to-severe plaque psoriasis, marking a major expansion of its specialty dermatology portfolio. The announcement was made through a regulatory filing on December 1, 2025.
According to the press release, Ilumya — already approved and used in 35 countries — has built a strong global reputation for delivering long-lasting skin clearance, high safety, and sustained efficacy for psoriasis patients. The drug is an IL-23 inhibitor that selectively targets the p19 subunit, reducing inflammatory cytokine activity responsible for psoriasis symptoms.
Strong results from Indian clinical studies
Sun Pharma conducted a dedicated Indian clinical study involving 115 patients, with results showing compelling improvements:
- ≥75% skin clearance (PASI 75) achieved by 62.3% (Week 12), 83.3% (Week 16) and 93.9% (Week 28)
- ≥90% skin clearance (PASI 90) achieved by 26.3% (Week 12), 50% (Week 16) and 78.1% (Week 28)
- Patients received three subcutaneous injections over 16 weeks (Day 1, Week 4, Week 16)
- No immunogenicity concerns reported
Dermatologists involved in the Indian Phase-3 trial highlighted significant improvements across all clinical measures and emphasized Ilumya’s long-term sustainability, especially valuable for chronic psoriasis management.
Addresses a major unmet need in India
Psoriasis affects 0.44–2.8% of India’s population and is increasingly recognized as a chronic systemic disease with metabolic and cardiovascular risks. Many patients remain inadequately controlled on older systemic therapies due to long-term safety, tolerability, and monitoring concerns. Ilumya aims to bridge this gap with a targeted therapy requiring minimal monitoring and offering durable results.
What Ilumya offers
- Humanized monoclonal antibody
- Treats adults eligible for systemic therapy or phototherapy
- Proven long-term efficacy (5-year pooled Phase-3 extension data)
- Simplified dosing for long-term disease control
Sun Pharma stated that bringing Ilumya to India is part of its strategy to expand access to innovative dermatology treatments already used widely in the U.S. and international markets.
